Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

IntelGenx receives FDA PDUFA date for RIZAFILM

The FDA accepted for review IntelGenx’s (TSX:IGX; OTCQB:IGXT) Class 2 response to a 2020 complete response letter for the company’s 505(b)(2) NDA for RIZAFILM VersaFilm for the treatment of acute migraine. The FDA has...

November 22, 2022

Markets

BTIG starts Cullinan Oncology at buy; PT $20

BTIG initiated coverage of Cullinan Oncology (NASDAQ:CGEM) with a “buy” rating and price target of $20, citing a burgeoning pipeline and unique biology that could open avenues for a broad range of opportunities. The...

November 21, 2022

Markets

Cantor ups Provention Bio PT on FDA T1D approval

Cantor Fitzgerald raised its price target for Provention Bio (NASDAQ:PRVB) to $16 from $12 and maintained an “overweight” rating after the FDA approved teplizumab (brand name, TZIELD) to delay the onset of Type 1...

November 18, 2022

Developments

Kiora doses first patient in Phase 1b retinitis pigmentosa trial

Kiora Pharmaceuticals (NASDAQ:KPRX) dosed the first patient in a first-in-human open-label clinical trial for KIO-301, intended to restore vision loss in patients with retinitis pigmentosa, a rare, inherited genetic eye...

November 17, 2022

Markets

Cantor starts KemPharm at OW; PT $20

Cantor Fitzgerald initiated coverage of KemPharm (NASDAQ:KMPH) with an “overweight’ rating and a 12-month discounted cash flow-based price target of $20. The stock closed at $4.39 on Nov. 16. “We think KemPharm’s...

November 17, 2022

Developments

Azura posts positive Phase 2b results in meibomian gland dysfunction

Azura Ophthalmics reported positive 3-month efficacy and safety results from its Phase 2b study of AZR-MD-001 0.5% in meibomian gland dysfunction (MGD), a leading cause of dry eye disease and contact lens discomfort...

November 17, 2022

Markets

Cantor starts Theratechnologies at OW; PT $9

Cantor Fitzgerald launched coverage of Theratechnologies (NASDAQ:THTX) with an “overweight” rating and $9 price target. The stock closed at $1.88 on Nov. 16. “We believe the peak sales potential of Theratechnologies’...

November 17, 2022

Developments

NeuroSense receives IND clearance for Phase 2b ALS study

The FDA cleared NeuroSense Therapeutics’ (NASDAQ:NRSN) IND for its Phase 2b PARADIGM study with its lead drug candidate, PrimeC, in the treatment of amyotrophic lateral sclerosis (ALS). PARADIGM is currently enrolling...

November 15, 2022

Developments

Raymond James sees high likelihood of CPT-1 reimbursement for Profound’s TULSA-PRO

Analyst Rahul Sarugaser, Ph.D., writes that there is a high likelihood that Profound Medical (NASDAQ:PROF) will receive a category-1 CPT code from the Centers for Medicare and Medical Services when it files an...

November 15, 2022

Markets

HCW ups Syros PT on optimism about AML data at ASH

H.C Wainwright raised its price target for Syros Pharmaceuticals (NASDAQ:SYRS) to $20 from $6, noting that the company’s tamibarotene “looks to shine during ASH ‘22” in December. The stock closed at $3.66 on Nov. 14...

November 15, 2022

Markets

SVB cuts Satsuma to MP after negative SUMMIT data

SVB Securities downgraded Satsuma Pharmaceuticals (NASDAQ:STSA) to “market perform” from “outperform” and slashed its price target to $1 from $15 after the company reported negative data for the Phase 3 SUMMIT trial of...

November 15, 2022

Developments

Lanier Biotherapeutics receives U.S. patent for IL-25 binding molecules

Lanier Biotherapeutics announced that the United States Patent and Trademark Office has issued U.S. Patent 11,492,397, entitled, “Neutralizing Monoclonal Antibodies to IL-25 and Uses Thereof.” The patent covers...

November 14, 2022

IntelGenx receives FDA PDUFA date for RIZAFILM

BTIG starts Cullinan Oncology at buy; PT $20

Cantor ups Provention Bio PT on FDA T1D approval

Kiora doses first patient in Phase 1b retinitis pigmentosa trial

Cantor starts KemPharm at OW; PT $20

Azura posts positive Phase 2b results in meibomian gland dysfunction

Cantor starts Theratechnologies at OW; PT $9

NeuroSense receives IND clearance for Phase 2b ALS study

Raymond James sees high likelihood of CPT-1 reimbursement for Profound’s TULSA-PRO

HCW ups Syros PT on optimism about AML data at ASH

SVB cuts Satsuma to MP after negative SUMMIT data

Lanier Biotherapeutics receives U.S. patent for IL-25 binding molecules

General

More